Financial Data and Key Metrics Changes - In Q4 2025, ISG reported revenues of $61.2 million, a 6% increase compared to the previous year, with a positive currency impact of $1.3 million [17] - Adjusted EBITDA for Q4 was $8.1 million, up 24% from $6.5 million in the prior year, resulting in an EBITDA margin of 13.2%, which is 189 basis points higher year-on-year [18] - For the full year, revenues reached $245 million, a 7% increase, with adjusted EBITDA exceeding $32 million, up 28% from the previous year [9][22] - Operating cash flow for the full year was $29 million, a 46% increase year-on-year [20] Business Line Data and Key Metrics Changes - Recurring revenues in Q4 were up 13% globally, driven by research and platform businesses, especially governance services [8] - For the full year, recurring revenues totaled $112 million, representing 46% of total revenues [8] - AI-related revenues accounted for nearly 35% of Q4 revenues, up from 30% for the full year, indicating a threefold increase from 2024 [6][9] Market Data and Key Metrics Changes - The Americas region generated $38 million in Q4, a 1% increase, while Europe saw revenues rise by 28% to $19 million [17] - Asia Pacific revenues were $3.9 million, down $1.1 million compared to the prior year, with a noted need for public sector spending to reignite growth [14][15] Company Strategy and Development Direction - ISG is focusing on AI-centered transformation services, with a dedicated AI Acceleration Unit established to enhance capabilities and client offerings [10][11] - The company aims to increase AI-related revenue from 30% to 50% and is actively pursuing M&A opportunities to bolster recurring revenues and AI initiatives [35][42] - The introduction of the AI Maturity Index is seen as a strategic tool to assess client readiness for AI adoption and open new client discussions [10][33] Management's Comments on Operating Environment and Future Outlook - Management noted that clients remain cautious in a macroeconomic environment but continue to invest in AI-related transformations [15] - The outlook for Q1 includes expected revenues in the range of $60.5 million to $61.5 million, with continued year-over-year growth anticipated [16] - The company is well-positioned to capitalize on the accelerating demand for AI-led transformation despite macroeconomic uncertainties [22] Other Important Information - The company ended the year with cash of $28.7 million, flat from the end of Q3 and up $5.6 million year-on-year [20] - The average borrowing rate for the quarter was 5.8%, down 125 basis points year-on-year, indicating improved financial health [20] Q&A Session Summary Question: Differentiation of client verticals and spending trends - Management indicated a mix of offensive and defensive spending across industries, with consumer sectors being more defensive while energy and health sciences are more offensive [28] Question: Insights on the AI Maturity Index and acquisition appetite - The AI Maturity Index is being used as a door opener for new client engagements, and the company is actively looking for M&A opportunities to enhance its AI journey [30][35] Question: Early wins for the AI Acceleration Unit - The goal is to increase AI-related revenue from 30% to 50%, leveraging a skilled workforce and ongoing training initiatives [42] Question: Visibility in the pipeline and sales cycles - The pipeline remains strong, but the pace of sales may be mixed due to macroeconomic factors, with expectations for acceleration in the latter half of the year [44] Question: Recurring revenue and AI spend - AI is becoming part of most projects, with some components being recurring, particularly in governance and research [47] Question: Labor supply and readiness for AI demand - The company has scaled its workforce in AI skills and is confident in meeting current demand while maintaining low turnover rates [55] Question: Service lines expected to lead in Q1 - AI and recurring revenue streams, particularly in Europe, are expected to drive growth in Q1 [57] Question: Growth drivers for ISG Tango - ISG Tango is performing well, with significant contract value running through the platform, particularly in the mid-market segment [88] Question: Catalysts for growth in Asia - Improvement in public sector spending is necessary for Asia to return to growth, with some early signs of better opportunities in the pipeline [93]

Kingstone Companies (NasdaqCM:KINS) Q4 2025 Earnings call March 06, 2026 08:30 AM ET Company ParticipantsBob Farnam - Managing DirectorMeryl Golden - President and Chief Executive OfficerRandy Patten - CFOStefan Norbom - Investor Relations RepresentativeConference Call ParticipantsGabriel McClure - AnalystOperatorGreetings, welcome to the Kingstone Companies' fourth quarter and full year 2025 earnings conference call. As a reminder, this conference is being recorded. I would now like to turn the call over t ...

Financial Data and Key Metrics Changes - The company reported full-year net earnings per share of $0.27 and Adjusted Net EPS of $0.34, exceeding the top end of guidance by $0.02 [11][35] - Full-year GAAP net earnings were $208 million, compared to $54.8 million in 2024, while adjusted net earnings increased by approximately 17% from $221.6 million in 2024 to $258.8 million [35] - Operating expenses as a percentage of gross revenue decreased from approximately 38% in 2024 to roughly 36% in 2025 [13] Business Line Data and Key Metrics Changes - The increase in adjusted net earnings was primarily driven by $10.3 million from new utility rates implemented across various systems [36] - New utility rates contributed $41.6 million of benefit from approved rate implementations across several gas, water, and electric systems throughout the year [40] - The regulated services group growth was driven by new rate implementations, favorable weather, lower interest expense, and depreciation deferral benefits [44] Market Data and Key Metrics Changes - The company operates in high-quality jurisdictions with attractive regulatory mechanisms, including tracker mechanisms and multi-year rate plans [29] - Recent legislative and regulatory developments in states like Missouri, Arizona, New Hampshire, and Oklahoma are enhancing investment recovery [30] Company Strategy and Development Direction - The company aims to become a premium pure-play regulated utility, focusing on operational discipline and regulatory strategy execution [10][19] - A centralized capital projects team is being implemented to improve execution and performance while maintaining affordability across all jurisdictions [15][16] - The capital expenditure outlook for 2026 through 2028 is approximately $3.2 billion, with a focus on safety, reliability, and service improvements [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2026 earnings guidance and highlighted the importance of disciplined execution and constructive regulatory engagement [19][54] - The effective tax rate for 2027 is now expected to be in the mid-to-high 20% range, impacting the adjusted net EPS estimate for that year [20][54] - Management emphasized the need for consistent operational standards and stakeholder engagement to improve customer outcomes and regulatory support [108] Other Important Information - The company strengthened its balance sheet by using net proceeds from the sale of its renewable business to retire approximately $1.6 billion of debt [14][49] - Total debt stands at approximately $6.5 billion, with a solid investment-grade credit rating and no expected equity issuance through 2027 [50] Q&A Session Summary Question: Can you share details on the revised 2027 guidance and the drivers behind the effective tax rate change? - Management indicated that the effective tax rate moved from low to mid-twenties to mid to high twenties, resulting in a $0.03 per share EPS deduction [62][63] Question: What are the largest levers the business can pull in the near term? - Management highlighted the importance of regulatory engagement and a strong balance sheet, providing flexibility for organic growth and potential opportunities [65] Question: Can you provide an update on the CalPeco solar project that was canceled? - The project was deemed economically unviable, and the decision to discontinue it was based on the inability to earn a fair return [90] Question: What is the company's view on the California regulatory backdrop regarding wildfire risk? - Management acknowledged the ongoing discussions about wildfire risk and the potential for contributing to a wildfire fund, but no specific decisions have been made [135]

Financial Data and Key Metrics Changes - The company reported a net loss of $7.7 million for 2025, an improvement compared to the previous year [25] - Cash position at the end of the year was $23 million, extending the cash runway into the second half of 2027 [26] - Total cash inflow for the year amounted to $32 million, driven by public offerings and the exercise of investor warrants [21][22] Business Line Data and Key Metrics Changes - The EVX-01 program, a personalized cancer vaccine, showed a high objective response rate of 75% and a complete response rate of 25% in a two-year phase 2 study [11] - The EVX-04 program for acute myeloid leukemia (AML) demonstrated strong preclinical evidence, with 16 optimal ERV antigen fragments identified [14] - The EVX-B2 program for gonorrhea retained full global rights, with strong preclinical data indicating significant protection in mouse models [16] Market Data and Key Metrics Changes - The company has seen significant interest in its AI-Immunology platform from various parties, including collaborations with MSD and The Gates Foundation [4][7] - The autoimmune disease market is being explored, with over 14 million patients affected annually in the U.S. [8] Company Strategy and Development Direction - The company aims to optimize its focus on assets that will add the most value, particularly in oncology and infectious diseases [34] - There is a commitment to deriving value from both the platform and pipeline assets through partnerships [9] - The AI-Immunology platform is being investigated for applications in autoimmune diseases, with plans to identify key indications for development [8][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AI-Immunology platform and its ability to generate meaningful clinical responses [33] - The company is positioned to advance through 2026, with ongoing discussions for potential partnerships [28] - Management highlighted the importance of building relationships and credibility with large pharmaceutical companies [62] Other Important Information - The company received recognition from the Galien Foundation for advances in AI in human health [6] - The automated vaccine design module launched in October 2025 enhances the design process, reducing costs and development time [19] Q&A Session Summary Question: Changes to strategy under new CEO - The fundamentals of the company remain strong, with a focus on optimizing value in oncology and infectious disease assets [34] Question: Regulatory submission for EVX-04 - The company is preparing for clinical trials and believes initial proof of concept will attract partner interest [36] Question: Partnering efforts for EVX-01 - The company is seeing interest in the cancer vaccine space, particularly due to strong clinical data and translational insights [46] Question: Application of AI-Immunology in autoimmune diseases - The company is analyzing prevalent autoimmune diseases to determine the best fit for its platform [76]

Kingstone Companies (NasdaqCM:KINS) Q4 2025 Earnings call March 06, 2026 08:30 AM ET Company ParticipantsMeryl Golden - President and Chief Executive OfficerRandy Patten - CFOStefan Norba - Investor Relations RepresentativeConference Call ParticipantsRobert Edward Farnam - Research AnalystOperatorGreetings, welcome to the Kingstone Companies' fourth quarter and full year 2025 earnings conference call. As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Stef ...

Financial Data and Key Metrics Changes - The company reported a net loss of $7.7 million for 2025, an improvement compared to the previous year [25] - Cash position at the end of the year was $23 million, extending the cash runway into the second half of 2027 [26] - Total cash inflow for the year amounted to $32 million, driven by public offerings and the exercise of investor warrants [21][22] Business Line Data and Key Metrics Changes - The EVX-01 program, a personalized cancer vaccine, showed a high objective response rate of 75% and a complete response rate of 25% in a two-year phase II study [11] - The EVX-04 program for acute myeloid leukemia (AML) demonstrated strong preclinical evidence, with 16 optimal ERV antigen fragments identified [14] - The EVX-B2 program targeting Neisseria gonorrhoeae retained full global rights, with strong preclinical data indicating significant protection in mouse models [16] Market Data and Key Metrics Changes - The company has seen significant interest in its AI-Immunology platform from various parties, including collaborations with MSD and The Gates Foundation [4][5] - The autoimmune disease market is being explored, with over 14 million patients affected annually in the U.S. [8] Company Strategy and Development Direction - The company aims to optimize its focus on assets that will add the most value, particularly in oncology and infectious diseases [34] - There is a commitment to deriving value from both the platform and pipeline assets through partnerships [9] - The AI-Immunology platform is being investigated for applications in autoimmune diseases, with plans to identify key indications for development [8][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AI-Immunology platform and its ability to generate meaningful clinical responses [32] - The company is positioned to advance through 2026, with ongoing discussions for potential partnerships [28] - Management highlighted the importance of building relationships and credibility with large pharmaceutical companies [62] Other Important Information - The company received recognition from the Galien Foundation for advances in AI in human health [6] - The automated vaccine design module launched in October 2025 significantly reduces costs and development time [19] Q&A Session Summary Question: Changes to strategy under new CEO - The CEO noted that while there are no fundamental changes to strategy, there is a sharpening of focus on high-value assets [34] Question: Regulatory submission for EVX-04 - The CEO indicated that the company is preparing to take EVX-04 into the clinic for initial proof of concept [36] Question: Partnering efforts for EVX-01 - The CEO mentioned that strong clinical data and translational insights are key to driving interest from potential partners [46] Question: Application of AI-Immunology in autoimmune diseases - The management confirmed ongoing analysis to identify the most prevalent autoimmune diseases for potential development [76]

Financial Data and Key Metrics Changes - For the fourth quarter, revenue reached $800 million, a 7% increase year-over-year, with adjusted EPS of $3.74, up $0.48 from last year [24][30] - Comparable sales rose 9%, with stores up 9% and direct sales up 8%, marking the strongest quarterly comp performance of the year [25][27] - Adjusted gross margin declined by 90 basis points, primarily due to heightened promotional activity at Schuh and ongoing tariff pressures [27][28] Business Line Data and Key Metrics Changes - Journeys led with a 12% growth in comparable sales, building on a 14% increase in Q4 last year, driven by strong demand for casual and athletic footwear [25][12] - Johnston & Murphy saw a 2% increase in comps, with sequential improvement noted in December and January [26] - Schuh's comps rose 3%, influenced by holiday promotional activity, but faced challenges due to a highly promotional environment [26][15] Market Data and Key Metrics Changes - The U.K. retail environment for Schuh remained competitive and promotional, leading to a lackluster holiday season for discretionary categories [15] - E-commerce penetration at Schuh exceeded 50% of sales, reflecting a shift towards value-driven online behavior [26] Company Strategy and Development Direction - The company is focused on a "Footwear First" strategy, emphasizing customer-centric initiatives and improving cost structures [51][72] - Key growth drivers include creating winning products, elevating retail brands, delivering exceptional consumer experiences, and building strong teams [52] - The company plans to double the number of 4.0 stores, enhancing the shopping experience and driving higher traffic and productivity [61][102] Management's Comments on Operating Environment and Future Outlook - The consumer environment remains selective, with demand accelerating during key shopping periods [8][9] - The company expects continued strength at Journeys, improvement at Johnston & Murphy, and a reset for Schuh to drive profitability in fiscal 2027 [34][49] - Management is optimistic about unlocking earnings opportunities across strategically positioned businesses while being mindful of evolving consumer needs [22][36] Other Important Information - The company ended the year with a positive net cash position and generated $164 million of free cash flow in Q4 [31][33] - Capital expenditures for the year are expected to be approximately $65 million-$70 million, primarily for store remodels and new openings [46] Q&A Session Questions and Answers Question: How is the Journeys business performing quarter to date? - Management reported that Journeys is tracking in the mid-single digits for February, with expectations for higher comps in the early part of the year due to anticipated tax refunds [76][78] Question: Can you discuss changes to the assortment for Journeys this year? - Management indicated that growth is expected from existing franchises rather than new brands, with a focus on deepening the assortment that resonates with consumers [82] Question: How much pressure did Schuh have on gross margin in 2026, and what recovery is anticipated in 2027? - Approximately 250 basis points of gross margin pressure was attributed to Schuh, with expectations for a significant recovery as promotions are reduced [85][87] Question: Can you provide insights on the canvas category performance and pipeline? - Management noted that while canvas remains relevant, they do not anticipate overall growth in the category for the year, focusing instead on casual and boots for growth [91] Question: What is the timing for store openings and closings? - The company plans to open 80 new 4.0 stores this year, with closures primarily occurring around lease expirations, predominantly in Q1 and Q2 [101][103]

Financial Data and Key Metrics Changes - For the fourth quarter, revenue reached $800 million, a 7% increase year-over-year, with adjusted EPS of $3.74, up $0.48 from last year [25][31] - Comparable sales rose 9%, with stores up 9% and direct sales up 8%, marking the strongest quarterly comp performance of the year [26][30] - Adjusted operating income was $56 million for the quarter, an increase of 17% compared to $48 million last year [31] Business Line Data and Key Metrics Changes - Journeys led with a 12% growth in comparable sales, building on a 14% increase in Q4 last year [26] - Johnston & Murphy saw a 2% increase in comps, with sequential improvement in December and January [27] - Schuh's comps rose 3%, driven by holiday promotional activity, with e-commerce penetration exceeding 50% of sales [27] Market Data and Key Metrics Changes - The U.K. retail environment for Schuh remained highly promotional and competitive, resulting in a lackluster holiday season [15] - The footwear market overall saw Journeys outperforming, gaining market share particularly among the youth customer base [13] Company Strategy and Development Direction - The company is focusing on a "Footwear First" strategy, emphasizing customer-centric initiatives and improving cost structures [52][73] - Plans include expanding the 4.0 store format, with an aim to double the number of these stores to enhance customer experience and drive sales [60][104] - The company aims to restore margin discipline at Schuh while prioritizing profitability over short-term comp gains [37][66] Management's Comments on Operating Environment and Future Outlook - The consumer environment remains selective, with demand accelerating during key shopping periods [8] - Management expressed confidence in achieving meaningful earnings opportunities across strategically positioned businesses, despite challenges [22][34] - The company anticipates continued strength at Journeys and improvement at Johnston & Murphy, while Schuh is expected to reset for profitability [34][40] Other Important Information - The company ended the year with a positive net cash position and generated $164 million of free cash flow in the fourth quarter [31][32] - Capital expenditures for the year are expected to be approximately $65 million-$70 million, primarily for store remodels and new openings [47] Q&A Session Summary Question: Performance of Journeys and comp expectations - Management indicated that Journeys is tracking in the mid-single digits for February, with expectations for higher comps in the early part of the year due to tax refunds [80] Question: Changes to the assortment for Journeys - Management noted that growth is expected from existing franchises rather than new brands, with a focus on meeting customer demands [85] Question: Gross margin pressure at Schuh - It was highlighted that about 60% of the gross margin deleverage in 2026 was attributable to Schuh, with expectations for recovery in 2027 [88][89] Question: Timing of store openings and closings - Management confirmed plans to open 80 new 4.0 stores, with closures primarily around lease expirations, predominantly in Q1 and Q2 [105] Question: Sales in licensed businesses - Management expects the most pressure from down sales in the second quarter, with plans to improve gross margins over time [112]

Financial Data and Key Metrics Changes - The company reported a net loss of $7.7 million for 2025, an improvement compared to the previous year [24] - Cash position at the end of the year was $23 million, extending the cash runway into the second half of 2027 [25] - Total cash inflow for the year amounted to $32 million, bolstered by public offerings and the exercise of investor warrants [19][20] Business Line Data and Key Metrics Changes - The EVX-01 program for advanced melanoma showed a high objective response rate of 75% and a complete response rate of 25% based on 2-year phase 2 data [10] - The EVX-04 program for acute myeloid leukemia (AML) demonstrated strong preclinical evidence, with 16 optimal ERV antigen fragments identified [12] - The EVX-B2 program targeting Neisseria gonorrhoeae retained full global rights, with strong preclinical data indicating significant protection in mouse models [14] Market Data and Key Metrics Changes - The company has seen significant interest in its AI-Immunology platform from various parties, including collaborations with MSD and The Gates Foundation [4][6] - The autoimmune disease market is characterized by over 14 million patients annually in the U.S., presenting a significant opportunity for the company's platform [7] Company Strategy and Development Direction - The company aims to optimize its focus on assets that will add the most value, particularly in oncology and infectious diseases [32] - The AI-Immunology platform is being investigated for applications in autoimmune diseases, with plans to identify key indications for development [51] - The company is committed to deriving value from its platform and pipeline assets through partnerships [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AI-Immunology platform and its ability to generate meaningful clinical responses [30] - The company is positioned to advance through 2026, with ongoing discussions for potential partnerships [27] - Management highlighted the importance of building relationships and credibility with large pharmaceutical companies [60] Other Important Information - The company received recognition from the Galien Foundation for its AI advances in human health [5] - The automated vaccine design module launched in October 2025 enhances the design cycle, reducing costs and development time [18] Q&A Session Summary Question: Changes to strategy under new CEO - The CEO noted that the fundamentals of the company remain strong, with a focus on optimizing value in oncology and infectious disease assets [30] Question: Regulatory submission for EVX-04 - The CEO indicated that while initial proof of concept is important, further validation data will strengthen the value proposition for external partners [34] Question: Partnering efforts for EVX-01 - The CEO mentioned that strong clinical data and translational insights are key to driving interest from potential partners [41] Question: Autoimmune disease strategy - The company is analyzing prevalent autoimmune diseases to identify suitable indications for its platform [72]

Financial Data and Key Metrics Changes - For the fourth quarter, revenue reached $800 million, a 7% increase year-over-year, with comparable sales rising 9% [16] - Adjusted EPS for the quarter was $3.74, up $0.48 from the previous year, while full-year adjusted EPS was $1.45, compared to $0.94 last year [15][19] - Adjusted operating income for the quarter was $56 million, a 17% increase from $48 million last year [19] Business Line Data and Key Metrics Changes - Journeys led the growth with a 12% increase in comparable sales, building on a 14% increase in the same quarter last year [16] - Johnston & Murphy saw a 2% increase in comparable sales, with improvements noted in December and January [17] - Schuh's comparable sales rose 3%, driven by holiday promotions, but faced challenges due to a highly promotional environment [17] Market Data and Key Metrics Changes - E-commerce penetration at Schuh exceeded 50% of sales, reflecting a shift towards online shopping in a promotional market [17] - The U.K. retail environment remained competitive and promotional, impacting Schuh's profitability during the holiday season [10] Company Strategy and Development Direction - The company is focusing on a "Footwear First" strategy, emphasizing customer-centric initiatives and improving cost structures [31][32] - Plans for Journeys include expanding the 4.0 store format, enhancing product assortments, and increasing brand awareness through marketing campaigns [36][35] - Schuh aims to improve profitability by reducing reliance on discounting and enhancing product offerings [39] Management's Comments on Operating Environment and Future Outlook - The consumer environment is described as selective, with demand peaking during key shopping periods [5] - Management expressed confidence in achieving growth despite external challenges, with a focus on evolving product offerings to meet changing consumer needs [13][14] - The company anticipates a flat sales outlook for fiscal 2027, with expected comparable sales growth of 1%-2% [22] Other Important Information - The company ended the year with a positive net cash position and generated $164 million in free cash flow during the fourth quarter [19][20] - Capital expenditures for the year are projected to be between $65 million and $70 million, primarily for store remodels and new openings [28] Q&A Session Summary Question: How is the Journeys business performing quarter to date? - Management reported mid-single-digit growth for Journeys in February, with expectations for higher comps in the early part of the year due to anticipated tax refunds [43][46] Question: Can you discuss changes to the assortment for Journeys? - The company is focusing on existing franchises for growth rather than solely adding new brands, with continued success expected from brands like Hoka and Nike [48][50] Question: How much pressure did Schuh face on gross margin in 2026? - Approximately 250 basis points of gross margin pressure was attributed to Schuh, with expectations for recovery in 2027 as promotional activities are reduced [51][54] Question: What is the timing for store openings and closures? - The company plans to open 80 new 4.0 stores this year, with closures primarily occurring around lease expirations [65][67] Question: How will the licensed businesses perform in the first half of the year? - The company expects significant pressure from licensed business sales, particularly in the second and third quarters, with plans to improve gross margins over time [72][74]